

Haesuk Park

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8760358/haesuk-park-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	921 citations	16 h-index	29 g-index
73 ext. papers	1,224 ext. citations	5 avg, IF	4.79 L-index

#	Paper	IF	Citations
64	Risk of Obstructive Sleep Apnea in Adults with Resistant Hypertension 2022 , 1, 26-32		
63	Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019. <i>JAMA Network Open</i> , 2021 , 4, e2133474	10.4	3
62	Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study. <i>Blood</i> , 2021 , 138, 4059-4059	2.2	0
61	Comparative Effectiveness and Safety of Extended Anticoagulant Therapy Among Medicare Beneficiaries with Venous Thromboembolism. <i>Blood</i> , 2021 , 138, 178-178	2.2	0
60	Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1409-1417	2.8	0
59	Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections. <i>Journal of Pharmacy Practice</i> , 2021 , 8971900211000216	1.3	0
58	Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida's Acute Pain Opioid Restriction Law. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 779-784	1.9	2
57	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. <i>Pharmacotherapy</i> , 2021 , 41, 710-721	5.8	0
56	Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey. <i>Journal of Asthma and Allergy</i> , 2021 , 14, 929-941	3.1	2
55	Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C. <i>Hepatology Communications</i> , 2021 , 5, 203-216	6	3
54	Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021 , 10, 317-325	4.8	1
53	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. <i>JCO Oncology Practice</i> , 2021 , OP2100140	2.3	0
52	The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. <i>Hepatology</i> , 2021 , 74, 566-581	11.2	2
51	US national trends in bariatric surgery: A decade of study. <i>Surgery</i> , 2021 , 170, 13-17	3.6	12
50	The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 873-881	1.9	1
49	Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH). <i>Heliyon</i> , 2021 , 7, e07727	3.6	0
48	Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines. <i>European Journal of Pediatrics</i> , 2021 , 1	4.1	0

47	Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. <i>American Journal of Preventive Medicine</i> , 2021 , 61, 576-584	6.1	1
46	Surveillance of patients with cirrhosis remains suboptimal in the United States. <i>Journal of Hepatology</i> , 2021 , 75, 856-864	13.4	6
45	Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1388-1402	1.9	1
44	Trends in Sexually Transmitted Infections in United States Ambulatory Care Clinics from 2005-2016.. <i>Journal of Clinical Medicine</i> , 2021 , 11,	5.1	1
43	Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States. <i>Journal of Asthma and Allergy</i> , 2020 , 13, 545-555	3.1	5
42	Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially Insured in the United States. <i>American Journal of Hypertension</i> , 2020 , 33, 999-1002	2.3	1
41	Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008-2017. <i>International Journal of Cardiology: Hypertension</i> , 2020 , 6, 100033	1.6	5
40	Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 851-866	2.8	11
39	Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2020 , 77, 188-195	2.2	8
38	Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 6-15	2.3	5
37	Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3159-3174	4	1
36	Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e201611	10.4	29
35	Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1592-1602	6.1	4
34	Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 705-710	6.7	3
33	Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 30-38	2.6	1
32	Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis. <i>Clinical Therapeutics</i> , 2020 , 42, e161-e176	3.5	0
31	Trends in HIV Preexposure Prophylaxis Prescribing in the United States, 2012-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 395-397	27.4	7
30	A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1520-1528	4	8

29	The association between proton pump inhibitor use and the risk of tuberculosis: A case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 830-839	2.6	1
28	Can apixaban prevent venous thromboembolism better than rivaroxaban? - AuthorsTreply. <i>Lancet Haematology,the</i> , 2019 , 6, e181-e182	14.6	
27	Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 28-36	6.7	38
26	Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. <i>Pharmacotherapy</i> , 2019 , 39, 912-920	5.8	6
25	Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. <i>Journal of Internal Medicine</i> , 2019 , 286, 711-722	10.8	31
24	Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. <i>Lancet Haematology,the</i> , 2019 , 6, e20-e28	14.6	43
23	Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 698-707	4	10
22	Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States. <i>Hepatology</i> , 2019 , 69, 1032-1045	11.2	31
21	Trends in Readmission Rates, Hospital Charges, and Mortality for Patients With Chronic Obstructive Pulmonary Disease (COPD) in Florida From 2009 to 2014. <i>Clinical Therapeutics</i> , 2018 , 40, 613-626.e1	3.5	9
20	Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. <i>Hepatology</i> , 2018 , 67, 492-504	11.2	44
19	Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. <i>PLoS ONE</i> , 2018 , 13, e0196452	3.7	4
18	Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2018 , 17, 102	8.7	14
17	Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. <i>Journal of Affective Disorders</i> , 2018 , 238, 542-546	6.6	14
16	Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). <i>BMC Nephrology</i> , 2018 , 19, 318	2.7	18
15	Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. <i>Scientific Reports</i> , 2018 , 8, 9969	4.9	6
14	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017 , 37, 662-668	7.9	16
13	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. <i>Medicine (United States)</i> , 2016 , 95, e5048	1.8	29
12	Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. <i>Gastroenterology</i> , 2016 , 150, 1599-1608	13.3	231

11	Real-world outcomes of ledipasvir/sofosbuvir in treatment-naïve patients with hepatitis C. <i>American Journal of Managed Care</i> , 2016 , 22, SP205-11	2.1	29
10	Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey. <i>Clinical Therapeutics</i> , 2015 , 37, 1466-1476.e1	3.5	23
9	Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015 , 21, 507-14	1.9	2
8	Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015 , 21, 956-64	1.9	4
7	Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase. <i>Journal of Managed Care Pharmacy</i> , 2014 , 20, 862-76		25
6	Scales of smoking-related self-efficacy, beliefs, and intention: assessing measurement invariance among intermittent and daily high school smokers. <i>American Journal of Health Promotion</i> , 2014 , 28, 310-5	3.5	7
5	Assessing the invariance of smoking-related self-efficacy, beliefs, and intention among high school current smokers. <i>Substance Use and Misuse</i> , 2013 , 48, 477-83	2.2	2
4	Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1453-69	2.9	76
3	Cost-effectiveness of expanded newborn screening in Texas. <i>Value in Health</i> , 2012 , 15, 613-21	3.3	20
2	Evaluation of health care costs and utilization patterns for patients with gout. <i>Clinical Therapeutics</i> , 2012 , 34, 640-52	3.5	37
1	Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. <i>Value in Health</i> , 2011 , 14, 1002-9	3.3	20